Home » Stocks » ADIL

Adial Pharmaceuticals, Inc. (ADIL)

Stock Price: $2.06 USD -0.01 (-0.48%)
Updated May 13, 2021 3:00 PM EDT - Market open
Market Cap 36.06M
Revenue (ttm) n/a
Net Income (ttm) -10.89M
Shares Out 17.50M
EPS (ttm) -0.87
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 13
Last Price $2.06
Previous Close $2.07
Change ($) -0.01
Change (%) -0.48%
Day's Open 2.05
Day's Range 1.98 - 2.10
Day's Volume 114,733
52-Week Range 1.14 - 4.00

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Discusses long-term effects of COVID-19 pandemic on mental health and addiction Discusses long-term effects of COVID-19 pandemic on mental health and addiction

1 month ago - GlobeNewsWire

CHARLOTTESVILLE, Va., March 15, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing th...

1 month ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial”), a clinical-stage biopharmaceutical company focused on the development of treatments f...

2 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the developmen...

2 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addicti...

2 months ago - GlobeNewsWire

CHARLOTTESVILLE, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on the developmen...

2 months ago - GlobeNewsWire

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2021 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW) ("Adial" or the "Company"), a clinical-stage biopharmaceutical company focused on the development o...

4 months ago - Accesswire

CHARLOTTESVILLE, VA / ACCESSWIRE / January 11, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions...

4 months ago - Accesswire

ONWARD™ Trial Remains on Track to be Fully Enrolled During Q2 2021 CHARLOTTESVILLE, VA / ACCESSWIRE / December 17, 2020 / Adial Pharmaceuticals, Inc. (NASDAQ:ADIL; ADILW), a clinical-stage biopharmaceut...

4 months ago - Accesswire

About ADIL

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

Industry
Biotechnology
IPO Date
Jul 30, 2018
Stock Exchange
NASDAQ
Ticker Symbol
ADIL
Full Company Profile

Financial Performance

Financial Statements